Skip to content

LOMA PHARMA

Active
Private limited companyfounded 2003active for 22 yearsMeensesteenweg 82, 8870 Izegem, BelgiumKBO/BCE: BE 0862.409.677
Summary

LOMA PHARMA has been active since 2003 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €359,511 and a net result of €115,678. Equity is growing by about 18% per year across the filed financial years. Its solvency ranks better than 44% of 12,482 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€1.2mtotal assets 2025
Staff
3.9 FTE
Equity
€359,511
Profit
€115,678
Turnover not published (abbreviated format)
Financial health
90 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.2%
Structure
Parent
NEWHOUSE PHARMACEUTICALS · 100%
Accounts filed 21 days late0 of 3 deeds read
Why 90raises riskSector: Retail trade (NACE 47)lowers riskFounded in 2003Figures for financial year 2025 (filed 21-08-2026)Size: 3.9 FTE, total assets €1.2mShow the evidence

Checked score

Score 2025
90 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 52% of its sector peers (NACE 47, micro)
Financial strength · tick = 2024
Average
Solvency 56+4
equity 31.2% of total assets
Liquidity 53-1
short-term debt 35.6% · cash 15.0%
Profitability 61-12
return on assets 10.1%
Bankruptcy probability, 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%

About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,186 companies, NACE 47, micro)
Last 24 months 11-2024: 0.2% 12-2024: 0.2%● unchanged vs 11-2024 01-2025: 0.3%▲ +0.1 percentage points vs 12-2024 02-2025: 0.3%● unchanged vs 01-2025 03-2025: 0.3%● unchanged vs 02-2025 04-2025: 0.5%▲ +0.2 percentage points vs 03-2025 05-2025: 0.9%▲ +0.4 percentage points vs 04-2025 06-2025: 1.1%▲ +0.2 percentage points vs 05-2025 07-2025: 1.5%▲ +0.4 percentage points vs 06-2025 08-2025: 1.5%● unchanged vs 07-2025highest value 09-2025: 0.2%▼ -1.3 percentage points vs 08-2025 10-2025: 0.2%● unchanged vs 09-2025 11-2025: 0.2%● unchanged vs 10-2025 12-2025: 0.2%● unchanged vs 11-2025 01-2026: 0.2%● unchanged vs 12-2025 02-2026: 0.2%● unchanged vs 01-2026 03-2026: 0.2%● unchanged vs 02-2026lowest value 04-2026: 0.2%● unchanged vs 03-2026 05-2026: 0.2%● unchanged vs 04-2026 06-2026: 0.2%● unchanged vs 05-2026 07-2026: 0.2%● unchanged vs 06-2026 08-2026: 0.6%▲ +0.4 percentage points vs 07-2026 09-2026: 0.2%▼ -0.4 percentage points vs 08-2026 10-2026: 0.2%● unchanged vs 09-2026
Credit of up to €30,000 on 30-day terms is acceptable
Liquidity ample (current ratio 1.72, compared with 1.6 in 2024; short-term debt: 35.6% and cash: 15% of total assets), but 68.8% of the assets are financed with debt.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 47% on solvency, 58% on liquidity, 43% on profitability and 59% on growth.

The bankruptcy probability was computed on 08-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
−lowers risk+raises risk○neutral
lowers risk · Founded in 2003
How long the company has existed counts in the probability; how much depends on the rest of its profile.
KBO
raises risk · Sector: Retail trade (NACE 47)
KBO
lowers risk · Figures for financial year 2025 (filed 21-08-2026)
NBB · annual accounts
lowers risk · Size: 3.9 FTE, total assets €1.2m
The company's size counts in the probability; how much depends on the rest of its profile.
NBB · annual accounts
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 21-08-2026, 21 days later. For context: 47% of Belgian companies file late, and of those that file 1 to 90 days late, 2.0% are now in a legal situation other than normal in the KBO (such as bankruptcy, liquidation or dissolution), against 1.66% of all filers. We show this as a fact and do not score it.
NBB · 10 filings
Deviation from the deadline
2025
21 days late
2024
13 days late
2023
12 days early
2022
5 days early
2021
4 days early
2020
8 days early
2019
1 day early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 1 day after the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Where today falls in the filing period
09-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · abbreviated…
  2. Annual accounts filedfinancial year 2024 · abbreviated…
  3. Highest result from 2019 to 2025net €153,714 ▲147%

Key points

  • Controlled by NEWHOUSE PHARMACEUTICALS 100% View
  • Positive: 7 profitable years in a rowprofit 2025: €115,678 7 years View
  • Total assets 20256 financial years filed €1.2m View

By topic

Financials

Financial year
2025
Total assets
€1.2m
Profit
€115,678
Solvency
31.2%
Total assets▼ 4.0%
Net result
20192025
Go to Financials

Timeline

Events
25
Since
2006
Next accounts
by 31-07-2027
  1. 18-04-2024Annual accounts filed
  2. 25-04-2023Annual accounts filed
  3. 30-09-2022Equity above €200,000
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
26-12-2003
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.